Mytesi ® is an FDA -approved anti-diarrheal prescription drug indicated for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on anti-retroviral therapy (ART) Mytesi ® is the fourth product being promoted by RedHill's gastrointestinal-focused U.S. ...
400 of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA ® for H. pylori infection (ERADICATE Hp2) RedHill expects to complete enrollment in the Phase III ERADICATE Hp2 study in coming weeks and announce top-line results in Q4/2018 ...
TEL-AVIV, Israel and RALEIGH, N.C. , July 23, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
RedHill has received Notices of Allowance for two new patents covering RHB-104 in the U.S. and Europe which are expected to be valid until at least 2029, once granted Top-line results from the first Phase III study with RHB-104 for Crohn’s disease are expected to be announced in the coming weeks ...
RedHill has been granted the exclusive right to co-promote Mytesi ® (crofelemer 125 mg delayed-release tablets) in the U.S. to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by Napo Pharmaceuticals , a subsidiary of Jaguar Health ...
TEL-AVIV , Israel and RALEIGH, N.C. , May 30, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
TEL-AVIV, Israel and RALEIGH, N.C. , May 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
Last patient completed treatment for primary endpoint assessment in the Phase III study with RHB-104 for Crohn’s disease; Top-line results expected to be announced in approximately 3 months TEL-AVIV, Israel and RALEIGH, N.C. , May 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. ...
Key Highlights: Top-line results from Phase III study with RHB-104 for Crohn’s disease (MAP US study) expected in approximately 3 months Top-line results from confirmatory Phase III study with TALICIA ® for H. pylori infection (ERADICATE Hp2 study) expected Q4/2018 Net revenues of $2.4 million and ...
Top-line results from the Phase III study with RHB-104 for Crohn’s disease are expected to be announced in approximately three months Worldwide sales of Crohn’s disease therapies are estimated to exceed $10 billion in 2018 Top-line results from the confirmatory Phase III study with TALICIA ® ...
Menu